Benefits of Breast Cancer Index
Video Categories: PMO Interview with the Innovator Series: Volume 8Related Videos

Navigating the CMS 14-Day Rule in Biomarker Testing
Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.

Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries
Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.